OmniComm Systems, Inc. Reports Financial Results for the Year Ended December 31, 2016

FORT LAUDERDALE, FL, March 30, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced record financial results for the year ended December 31, 2016.

“The year of 2016 has been another record-breaking year in a string of very successful years,” said Stephen Johnson, OmniComm’s president and chief operating officer. “The strength of our product lines, our commitment to innovation and excellent customer service continue to propel our company forward. Our business in international markets continues to expand and our core product line, TrialMaster®, saw record contract and revenue results across all four quarters in both repeat and new business. This is a testament to the hard work our people have put into this company and to the loyal support our customers have given us. We are excited about our future prospects and look forward to delivering more innovative solutions that ultimately help improve patient quality of life and outcomes.”

For the year ending December 31, 2016, OmniComm reported record revenue of $25.4 million, a 23% increase over the prior year’s revenue of $20.7 million. Gross margin improved by 23% or $3.8 million to $20.0 million. Operating expenses increased by 6% or $0.9 million to $15.9 million, which resulted in operating income of $4.2 million, a 233% increase over 2015 operating income results. EBITDA, a non-GAAP financial measure OmniComm uses as an additional financial measure, improved by $3.0 million or 195% to $4.5 million.

“I am extremely pleased with our 2016 financial results,” said Cornelis Wit, OmniComm’s chief executive officer. “These strong results, with significant improvements in both top-line revenue and operating income, clearly demonstrate OmniComm’s ability to provide the life sciences sector with products and services that improve the clinical trial process.”

OmniComm provides EBITDA, a non-GAAP financial measure as additional information to its financial results. Non-GAAP EBITDA excludes the impact of depreciation and amortization expenses that are included in operating income. Non-GAAP EBITDA is not an alternative or substitute for the financial measure prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) of operating income. The non-GAAP EBITDA financial measure presented may differ from similarly titled non-GAAP financial measures presented by other companies, and other companies may not define this non-GAAP financial measure in the same way. OmniComm’s management uses non-GAAP EBITDA as a measure of operational efficiency and as a goal for incentive compensation. Management believes non-GAAP EBITDA is a useful measure investors may use as an additional factor in their analysis of OmniComm’s performance. Please review the below reconciliation of the non-GAAP financial measure EBITDA to the GAAP financial measure operating income, as well as OmniComm’s financial statements as filed with the Securities and Exchange Commission.

Reconciliation of GAAP operating income to non-GAAP EBITDA
For the year ended
December 31,
2016 2015
Operating income/(loss) (GAAP)4,165,231 1,252,230
Depreciation expense302,893 233,798
Amortization expense37,331 40,338
EBITDA (non-GAAP)4,505,455 1,526,366

Forward-Looking Statements
Statements contained in this press release that are not historical facts are "forward-looking statements." These statements can often be identified by the use of forward-looking terminology such as "estimate," "project," "believe," "expect," "may," "will," "should," "intends," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements regarding matters that are not historical facts are only predictions and are based on information available at the time and/or management's good faith belief with respect to future events. No assurance can be given that plans for the future will be consummated or that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, these plans and projections and other forward-looking statements are based upon a variety of assumptions, which we consider reasonable, but which nevertheless may not be realized. Because of the number and range of the assumptions underlying our projections and forward-looking statements, many of which are subject to significant uncertainties and contingencies that are beyond our reasonable control, some of the assumptions inevitably will not materialize, and unanticipated events and circumstances may occur subsequent to the date of this press release. Therefore, our actual experience and results achieved during the period covered by any particular projections or forward-looking statements may differ substantially from those projected. Consequently, the inclusion of projections and other forward-looking statements should not be regarded as a representation by us or any other person that these plans will be consummated or that estimates and projections will be realized, and actual results may vary materially. There can be no assurance that any of these expectations will be realized or that any of the forward-looking statements contained herein will prove to be accurate. Forward-looking statements speak only as of the date the statement was made. OmniComm does not undertake any obligation to update or revise any forward-looking statement made by it or on its behalf, whether as a result of new information, future events or otherwise.

For the year ended
December 31,
2016 2015
Revenues $24,394,010 $20,023,733
Reimbursable revenues 1,025,500 687,104
Total revenues 25,419,510 20,710,837
Cost of goods sold 3,913,407 3,770,013
Reimbursable expenses-cost of goods sold 1,461,425 677,568
Total cost of sales 5,374,832 4,447,581
Gross margin 20,044,678 16,263,256
Operating expenses
Salaries, benefits and related taxes 11,383,727 10,602,686
Rent and occupancy expenses 1,071,363 972,862
Consulting services 185,340 253,626
Legal and professional fees 364,859 415,834
Travel 774,379 779,817
Telephone and internet 164,014 166,361
Selling, general and administrative 1,462,774 1,530,765
Bad debt expense 132,767 14,939
Depreciation expense 302,893 233,798
Amortization expense 37,331 40,338
Total operating expenses 15,879,447 15,011,026
Operating income/(loss) 4,165,231 1,252,230
Other income/(expense)
Interest expense, related parties (918,189) (2,434,101)
Interest expense (421,713) (299,668)
Interest income 2 4
Change in derivative liabilities (2,657,910) 4,525,798
Impairment of goodwill -0- (536,285)
Other income -0- 124,373
Transaction gain/(loss) (64,472) (70,706)
Income/(loss) before income taxes 102,949 2,561,645
Income tax (expense) (1,069) 24,739
Net income/(loss) 101,880 2,586,384
Preferred stock dividends
Preferred stock dividends in arrears
Series A preferred -0- (181,886)
Total preferred stock dividends -0- (181,886)
Net income/(loss) attributable to common stockholders$101,880 $2,404,498
Net income/(loss) per share
Basic $0.00 $0.02
Diluted $0.00 $0.02
Weighted average number of shares outstanding
Basic 145,868,227 96,645,482
Diluted 146,162,427 113,545,741

December 31, 2016 December 31, 2015
Cash $1,439,332 $835,219
Accounts receivable, net of allowance for doubtful accounts of $179,813 and $116,834, respectively 5,455,210 4,092,472
Prepaid expenses 195,915 170,173
Prepaid stock compensation, current portion 148,422 175,858
Other current assets 35,055 14,351
Total current assets 7,273,934 5,288,073
Property and equipment, net 637,552 683,712
Other assets
Intangible assets, net 108,880 148,877
Prepaid stock compensation 58,663 150,085
Other assets 51,321 46,565
TOTAL ASSETS $8,130,350 $6,317,312
Accounts payable and accrued expenses $2,123,073 $1,957,270
Deferred revenue, current portion 7,250,061 7,054,614
Convertible notes payable, current portion 50,000 75,000
Patent settlement liability, current portion 862,500 962,500
Conversion feature liability, related parties 1,740,278 535,835
Conversion feature liability 585,452 365,408
Warrant liability, related parties 2,519,614 1,353,786
Warrant liability 1,479,748 561,137
Total current liabilities 16,610,726 12,865,550
Line of credit, long term 2,700,000 4,200,000
Notes payable, related parties, long term, net of current portion, net of discount of $237,664 and $-0-, respectively 212,336 20,000
Notes payable, long term, net of current portion, net of discount of $455,285 and $-0-, respectively 337,215 792,500
Deferred revenue, long term, net of current portion 2,289,169 2,193,163
Convertible notes payable, related parties, long term, net of current portion 5,825,000 5,850,000
Convertible notes payable, long term, net of current portion 1,175,000 1,350,000
Patent settlement liability, long term, net of current portion 108,702 464,573
TOTAL LIABILITIES 29,258,148 27,735,786
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 3,772,500 shares undesignated -0- -0-
Series B convertible preferred stock, 230,000 shares authorized, -0- and -0- issued and outstanding,
respectively at $0.001 par value; liquidation preference $-0- and $-0-, respectively -0- -0-
Series C convertible preferred stock, 747,500 shares authorized, -0- and -0- issued and outstanding,
respectively at $0.001 par value; liquidation preference $-0- and $-0-, respectively -0- -0-
Series A convertible preferred stock, 5,000,000 shares authorized, -0- and 3,637,724 issued and outstanding,
respectively at $0.001 par value; liquidation preference $-0- and $3,637,724, respectively -0- 3,637
Series D preferred stock, 250,000 shares authorized, 250,000 and 250,000 issued and outstanding,
respectively at $0.001 par value 250 250
Common stock, 500,000,000 shares authorized, 147,786,917 and 131,703,577 issued and outstanding,
respectively at $0.001 par value 147,788 131,704
Additional paid in capital - preferred 999,750 4,230,792
Additional paid in capital - common 53,425,956 49,974,415
Accumulated other comprehensive (loss) (410,505) (366,355)
Accumulated (deficit) (75,291,037) (75,392,917)
TOTAL SHAREHOLDERS' (DEFICIT) (21,127,798) (21,418,474)

For the year ended
December 31,
2016 2015
Net income/(loss)$101,880 $2,586,384
Adjustment to reconcile net income/(loss) to net cash provided by/(used in) operating activities
Change in derivative liabilities 2,657,910 (4,525,798)
Impairment of goodwill -0- 536,285
Interest expense from derivative instruments 158,068 611,089
Employee stock compensation 222,304 245,083
Provision for doubtful accounts 132,767 14,939
Depreciation and amortization 340,224 274,136
Changes in operating assets and liabilities
Accounts receivable (1,495,505) (691,260)
Prepaid expenses (25,742) 57,909
Other current assets (20,704) 3,954
Other assets (4,756) 2,527
Accounts payable and accrued expenses 615,803 733,085
Patent settlement liability (455,871) (205,252)
Deferred revenue 291,453 1,013,834
Net cash provided by/(used in) operating activities 2,517,831 656,915
Purchase of property and equipment (260,378) (450,707)
Net cash (used in) investing activities (260,378) (450,707)
Repayments of notes payable (245,000) (75,000)
Proceeds/(repayments) from revolving line of credit (1,500,000) 200,000
Proceeds from exercise of stock options 129,500 27,250
Net cash provided by/(used in) financing activities (1,615,500) 152,250
Effect of exchange rate changes on fixed and intangible assets 6,310 76,375
Effect of exchange rate changes on cash and cash equivalents (44,150) (122,528)
Net increase/(decrease) in cash and cash equivalents 604,113 312,305
Cash and cash equivalents at beginning of period 835,219 522,914
Cash and cash equivalents at end of period$1,439,332 $835,219

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 5,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. For more information, visit:

OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Contact Info Investor Relations OmniComm Systems, Inc. +1.954.473.1254

Source:OmniComm Systems Inc.